LONDON, Nov. 21, 2024 /PRNewswire/ -- GenScript Biotech Corporation, a global leader in life sciences R&D and manufacturing services, successfully hosted the European debut of its GenScript Biotech ...

In the rapidly evolving world of cancer treatments, CAR-T cell therapy stands out for its effectiveness tackling hematologic tumors. Booming demand for such therapies powered Legend Biotech Corp. LEGN ...

The MarketWatch News Department was not involved in the creation of this content. PISCATAWAY, N.J., Nov. 21, 2025 /PRNewswire/ -- GenScript Biotech Corporation, a global leader in life sciences R&D ...

Recent price moves and business snapshot Genscript Biotech (SEHK:1548) has seen the stock slip about 0.5% on the day and roughly 5.6% over the past week, while posting a gain of around 13% over the ...

SAN FRANCISCO--(BUSINESS WIRE)--Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, and GenScript Biotech Corporation ...

GenScript Biotech Corporation (HKEX: 1548), a global company providing life science research services and products, biologics development & manufacturing services, and industrial biotechnology ...

After a financial maneuver by Legend Biotech, GenScript Biotech no longer considers itself the cell therapy biotech’s majority shareholder. (pengtianli/iStock/Getty ...

Analysts expect annual sales of Carvykti, Legend Biotech’s core cancer therapy, to peak at $7.3 billion With about $2 billion in cash reserves, Genscript isn’t under pressure to sell its 48% holding ...

Genscript Biotech ( (HK:1548)) has shared an update. Genscript Biotech reported that its associate Legend Biotech generated approximately US$597 million in net trade sales from the CARVYKTI® therapy ...

GENSCRIPT BIOTECH (01548.HK) announced that its subsidiary Legend Biotech, pursuant to its collaboration and license agreement with Janssen Biotech, recorded net trade sales of app... Open a new ...